Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 25 versus HYDRO SERP 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 25 versus HYDRO SERP 50.
ALDORIL 25 vs HYDRO-SERP "50"
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines (norepinephrine, dopamine) from peripheral sympathetic nerve endings, reducing vascular tone and heart rate.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Hydrochlorothiazide 50 mg orally once daily.
None Documented
None Documented
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
50-100 hours (prolonged in renal impairment; half-life up to 200 hours in severe renal disease)
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Renal (50-70% as unchanged drug and metabolites), biliary/fecal (20-30%)
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination